- 000 - 123 - 456789
- info@hellenicaesthetics.com
- No: 58 A, East Madison Street, Baltimore, MD, USA 4508
Androgenetic alopecia is the most prevalent type of hair loss in men and a leading cause of thinning in women. It can manifest at any age, including during childhood or adolescence, making it a condition that requires timely attention.
The emotional, social, and professional effects of androgenetic alopecia can be considerable for both men and women. In men, where thick hair is often linked with youthfulness, vitality, and masculinity, early hair loss can impact confidence, social relationships, and professional self-image. For women, whose hair is traditionally associated with femininity and beauty, noticeable thinning can lead to a loss of self-esteem, reduced social engagement, and emotional distress.
Given these challenges, early diagnosis and the initiation of suitable treatment are crucial steps in managing androgenetic alopecia effectively and restoring both appearance and confidence.
The four primary treatment options for androgenetic alopecia include:
Hormonal therapy is particularly effective for younger patients (up to 30 years old) and those in the early to moderate stages of hair loss (Norwood-Hamilton scale stages I–IV). As age increases, the therapy becomes less effective due to decreased androgen levels.
In men over 50, hormonal therapy is generally avoided, as it can reduce PSA (prostate-specific antigen) levels and potentially mask signs of prostate cancer.
In women, hormonal therapy is considered post-menopause. It may include:
The only proven non-hormonal treatment is Minoxidil, available in 2% or 5% topical solutions (lotion or foam). It should be applied at a dose of 1 ml, twice daily.
Minoxidil is best suited for slowing or reversing early-stage hair loss and requires consistent application for sustained benefits.
The surgical treatment for androgenetic alopecia involves hair transplantation, which is currently the only definitive and permanent solution for hair loss.
Modern non-invasive treatments include therapies based on autologous growth factors (often referred to as PRP – Platelet-Rich Plasma therapy).
This therapy is safe, natural, and highly effective as a conservative treatment option for androgenetic alopecia.
Androgenetic alopecia in men typically presents as a progressive thinning and loss of hair in specific areas:
Despite progression, a horseshoe-shaped band of hair usually remains intact along the sides and back (occipital area) of the scalp.
Complete baldness is uncommon, and the pattern of hair loss is key to diagnosis.
In women, androgenetic alopecia typically presents as diffuse thinning across the scalp, particularly at the crown and central parting, while the frontal hairline remains preserved.
Unlike men, women rarely experience complete baldness in affected areas. The thinning is usually more evenly spread, with density loss rather than patchy hair loss, making the condition more subtle but often emotionally impactful.
The phototrichogram is the most advanced diagnostic tool for detecting alopecia in both men and women. It utilizes a high-resolution digital microcamera combined with Follysis software to analyze and compare images from both affected and healthy scalp areas.
A reduction in hair shaft diameter is one of the earliest signs indicating the onset or progression of alopecia. This precise evaluation allows for early diagnosis and helps tailor the most effective treatment plan.
For the classification of the degree and severity of androgenetic alopecia, Norwood-Hamilton scale is used for male androgenetic alopecia and the Ludwig scale for female androgenetic alopecia.
It is estimated that 70% of men and 40% of women will experience it at some point in their lives, and one in two men will suffer from it at the age of 50.
Androgenetic alopecia in men is primarily caused by the influence of male sex hormones—androgens—on hair follicles, combined with a genetic predisposition. Androgens, especially dihydrotestosterone (DHT), play a key role in regulating sebaceous gland function and promoting body and facial hair growth. However, they also inhibit hair growth in the frontal and temporal regions of the scalp, leading to male pattern baldness.
In men affected by androgenetic alopecia:Both genetic and environmental factors contribute to the development of this condition. Although the complete mechanism remains not fully understood, certain health conditions such as mental health disorders, cardiovascular diseases, and prostate cancer have been linked to an increased risk of androgenetic alopecia.
Genetically, the condition is believed to be linked to genes located on the X chromosome, which are inherited from the mother. Since males have only one X chromosome, the presence of a single defective gene can trigger the condition. In contrast, women require the defective gene on both X chromosomes to manifest symptoms, making it less common and usually less severe in females.
Recent studies suggest a more complex genetic background, with additional genes influencing the onset age, progression rate, and pattern of hair loss.
While genetic predisposition plays a key role in female androgenetic alopecia, several other contributing factors have been identified. One of the most significant is the decline in estrogen levels during menopause, which disrupts the hormonal balance and promotes the action of androgens on hair follicles.
Additional causes include:
A recent study involving identical female twins also identified lifestyle and health-related factors associated with an increased risk of developing androgenetic alopecia. These include:
Environmental exposures like excessive sun exposure and not wearing protective headwear (e.g., hats) can also contribute to the condition by damaging scalp health over time.
Lastly, chronic stress and anxiety are known to accelerate hair thinning and loss in both women and men, making early identification and management of these triggers essential for slowing the progression of alopecia.